Financial Updates for the Psychedelics Industry | Page 3 of 9 | Microdose

Psychedelics News

Finance

16 May 2023

Q1 Psychedelics Report: Reform, Research, and Raises

As we move into the 2nd quarter of 2023, we take a look at Q1 and other trends in the psychedelic medicine sector...

By Alp Ergin

Finance

12 May 2023

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

COMPASS Pathways reported its financial results for the first quarter 2023 and gave an update on recent progress across its business....

By Microdose NewsDesk

Finance

12 May 2023

GH Research Reports First Quarter 2023 Financial Results and Business Highlights

GH Research has reported financial results for the first quarter ended March 31, 2023 and provided business highlights....

By Microdose NewsDesk

Finance

11 May 2023

Terran Biosciences announces publication of four patent applications of novel empathogens

Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Finance

8 May 2023

Which Psychedelic Medicine Companies Have the Best Financials?

As I have written many times before, the success or failure of a psychedelic medicine company depends heavily on its financial position....

By James Hallifax

Finance

4 Apr 2023

Enveric Biosciences Reports Q4 and Year-End 2022 Results

Enveric Biosciences, Inc....

By Microdose NewsDesk

Finance

3 Apr 2023

Chrisitian Angermayer Shows Faith in Atai, Buys Another 1.2 M Shares

On March 29th, Christian Angermayer, Founder and Chairman of atai Life Sciences (Nasdaq: ATAI), announced that he was buying more shares of the psychedelic medicines and biotechnology company....

By James Hallifax

Finance

24 Feb 2023

Transcend Therapeutics Announces $40 million Series A Funding

Transcend Therapeutics, a mental health-focused biotechnology company, announces Series A funding round of $40 million led by Alpha Wave Global and Integrated Investment Partners...

By Microdose NewsDesk

Finance

14 Feb 2023

Cybin Reports Q3 Financial Results and Business Highlights

Cybin has released its Q3 financial results and business highlights....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result